Bristol-Myers Squibb BMY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $48.48B+1.8% | $48.19B-0.2% | $48.03B+1.3% | $47.7B+2.6% | $47.64B+4.6% | ||
| $14.33B+1.8% | $13.94B-0.2% | $14.65B+23.1% | $14.17B+23.8% | $14.07B+27.2% | ||
| $34.16B+1.8% | $34.26B-0.2% | $33.38B-6.1% | $33.53B-4.4% | $33.57B-2.6% | ||
| 70.5%0.0pp | 71.1%0.0pp | 69.5%-5.4pp | 70.3%-5.1pp | 70.5%-5.2pp | ||
| $10.34B-3.5% | $9.95B-10.8% | $10.56B+1.1% | $10.4B+0.9% | $10.72B+10.8% | ||
| $7.3B-4.3% | $7.27B-13.6% | $7.22B-13.5% | $7.42B-11.4% | $7.63B-8.9% | ||
| $38.89B-6.4% | $38.87B-31.4% | $40B-26.4% | $41.11B-22.3% | $41.53B-19.2% | ||
| $9.6B+61.8% | $9.33B+209% | $7.86B+214% | $6.42B+200% | $5.93B+201% | ||
| $2.32B+246% | $2.27B+310% | $1.99B— | $1.53B— | $671M— | ||
| $7.28B+36.1% | $7.05B+178% | $5.97B+182% | $4.98B+176% | $5.35B+187% | ||
| 15%+3.8pp | 14.6%+33.3pp | 12.4%+27.7pp | 10.4%+24.5pp | 11.2%+24.7pp | ||
| $3.56+35.4% | $3.45+177% | $2.92+181% | $2.44+175% | $2.63+185% | ||
| $13.19B-5.9% | $13.34B+1,175% | $12.77B+287% | $12.92B+258% | $14.01B+249% | ||
| 27.2%-2.2pp | 27.7%+25.5pp | 26.6%+19.6pp | 27.1%+19.3pp | 29.4%+20.6pp | ||
| $9.6B+61.8% | $9.33B+209% | $7.86B+214% | $6.42B+200% | $5.93B+201% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bristol-Myers Squibb's revenue?
- Bristol-Myers Squibb (BMY) generated $48.5B in revenue over the trailing twelve months, up 1.8% year over year.
- Is Bristol-Myers Squibb profitable?
- Bristol-Myers Squibb reported $7.3B in net income over the trailing twelve months, a 15.0% net margin.
- What is Bristol-Myers Squibb's earnings per share?
- Bristol-Myers Squibb's diluted EPS over the trailing twelve months is $3.56.
- Where does Bristol-Myers Squibb's income statement data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
